References
- Aranda-Abreu GE, Hernández-Aguilar ME, Manzo Denes J, García Hernández LI, Herrera Rivero M. 2011. Rehabilitating a brain with Alzheimer’s: A proposal. Clin Interv Aging 6:53–59.
- Coleman BR, Ratcliffe RH, Oguntayo SA, Shi X, Doctor BP, Gordon RK, Nambiar MP. 2008. [+]-Huperzine A treatment protects against N-methyl-D-aspartate-induced seizure/status epilepticus in rats. Chem Biol Interact 175:387–395.
- Finder VH. 2010. Alzheimer’s disease: A general introduction and pathomechanism. J Alzheimers Dis 22:5–19.
- Haigh JR, Johnston SR, Peppernay A, Mattern PJ, Garcia GE, Doctor BP, Gordon RK, Aisen PS. 2008. Protection of red blood cell acetylcholinesterase by oral huperzine A against ex vivo soman exposure: Next generation prophylaxis and sequestering of acetylcholinesterase over butyrylcholinesterase. Chem Biol Interact 175:380–386.
- Howes MJ, Perry E. 2011. The role of phytochemicals in the treatment and prevention of dementia. Drugs Aging 28:439–468.
- Kaplan B, Çetin F, Elbeg S. 2010. The effects of vitamin C administration, acute food deprivation, and acute food intake on vitamin C levels in different brain areas of guinea pigs. Int J Vitam Nutr Res 80:197–204.
- Li C, Du F, Yu C, Xu X, Zheng J, Xu F, Zhu D. 2004. A sensitive method for the determination of the novel cholinesterase inhibitor ZT-1 and its active metabolite huperzine A in rat blood using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 18:651–656.
- López-Mirabal HR, Winther JR. 2008. Redox characteristics of the eukaryotic cytosol. Biochim Biophys Acta 1783:629–640.
- Ma XC, Wang HX, Xin J, Zhang T, Tu ZH. 2003. Effects of huperzine A on liver cytochrome P-450 in rats. Acta Pharmacol Sin 24:831–835.
- Maturu P, Reddy VD, Padmavathi P, Varadacharyulu N. 2011. Ethanol induced adaptive changes in blood for the pathological and toxicological effects of chronic ethanol consumption in humans. Exp Toxicol Pathol. (In Press).
- Pohanka M. 2011. Alzheimer’s disease and related neurodegenerative disorders: Implication and counteracting of melatonin. J Appl Biomed. J Appl Biomed 9:185–196.
- Pohanka M, Sobotka J, Svobodova H, Stetina R. 2011a. Investigation of oxidative stress in blood, brain, kidney, and liver after oxime antidote HI-6 application in a mouse experimental model. Drug Chem Toxicol 34:85–91.
- Pohanka M, Sobotka J, Stetina R. 2011b. Sulfur mustard induced oxidative stress and its alteration by epigallocatechin gallate. Toxicol Lett 201:105–109.
- Rafi MS, Walsh S, Little JT, Behan K, Reynolds B, Ward C, Jin S, Thomas R, Aisen PS; Alzheimer’s Disease Cooperative Study. 2011. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology 76:1389–1394.
- Sabbagh MN. 2009. Drug development for Alzheimer’s disease: Where are we now and where are we headed? Am J Geriatr Pharmacother 7:167–185.
- Schliebs R, Arendt T. 2006. The significance of the cholinergic system in the brain during aging and in Alzheimer’s disease. J Neural Transm 113:1625–1644.
- Wang J, Zhang HY, Tang XC. 2010. Huperzine a improves chronic inflammation and cognitive decline in rats with cerebral hypoperfusion. J Neurosci Res 88:807–815.
- Xiao XQ, Zhang HY, Tang XC. 2002. Huperzine A attenuates amyloid β-peptide fragment 25-35-induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and caspase-3 activation. J Neurosci Res 67:30–36.
- Zhang RW, Tang XC, Han YY, Sang GW, Zhang YD, Ma YX, Zhang CL, Yang RM. 1991. Drug evaluation of huperzine A in the treatment of senile memory disorders. Zhongguo Yao Li Xue Bao 12:250–252.
- Zhang HY, Tang XC. 2006. Neuroprotective effects of huperzine A: New therapeutic targets for neurodegenerative disease. Trends Pharmacol Sci 27:619–625.
- Zhang HY, Yan H, Tang XC. 2008. Non-cholinergic effects of huperzine A: Beyond inhibition of acetylcholinesterase. Cell Mol Neurobiol 28:173–183.